|
|||||
|
|
Atenolol in Migraine Prophylaxis a Double-blind Cross-over Multicentre Study |
|
| Authors: | Valur Johannsson,M.D., Lars R. Nilsson,M.D., Tommy Widelius,M.D., Tommy Jä verfalk,M.D., Peter Hellman,M.D., Jan-Å ke Å kesson,M.D., Bengt Olerud,M.D., CarI-Lennart Gustafsson,M.D., Anders Raak,M.D., Gun Sandahl,M.D., Bjö rn Tilling,M.D., Gö ran Almkvist,M.D., Margareta Troein,M.D. |
| Affiliation: | Linköping; Vansbro; Hofors; Mjölby; Gävle; Stockholm; Åtvidaberg; Luleå |
| Abstract: | SYNOPSIS The prophylactic anti-migraine effect of atenolol was compared to placebo in a multicentre study on 63 patients with classical and/or common migraine. The study design was double-blind cross-over and patients were given atenolol 100 mg o.d. or matching placebo during a study treatment period of 24 weeks. The effect of atenolol was significantly better than that of placebo: integrated headache values were reduced in 70% of the patients (p = 0.004) and the proportion of days with headache was reduced in 59% of the patients (p = 0.010). Few side effects were reported with both atenolol and placebo. This study shows atenolol to be safe and effective in the prophylactic treatment of migraine. |
| Keywords: | |